Baseline predictors of persistence to first disease‐modifying treatment in multiple sclerosis

Objectives Patients with multiple sclerosis (MS) require lifelong therapy. However, success of disease‐modifying therapies is dependent on patients' persistence and adherence to treatment schedules. In the setting of a large multicenter observational study, we aimed at assessing multiple parame...

Full description

Saved in:
Bibliographic Details
Published in:Acta neurologica Scandinavica 2017-08, Vol.136 (2), p.116-121
Main Authors: Zettl, U. K., Schreiber, H., Bauer‐Steinhusen, U., Glaser, T., Hechenbichler, K., Hecker, M.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Adult
Cohort Studies
depression
Depression - diagnosis
Depression - drug therapy
Depression - psychology
Education
Fatigue
Fatigue - diagnosis
Fatigue - drug therapy
Fatigue - psychology
Female
Follow-Up Studies
Humans
Interferon
Interferon beta-1b - therapeutic use
interferon beta‐1b
Male
Medication Adherence - psychology
Middle Aged
Multiple sclerosis
Multiple Sclerosis - diagnosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis - psychology
prediction analysis
Predictive Value of Tests
Prospective Studies
Quality of life
Quality of Life - psychology
therapy persistence
Treatment Outcome
Young Adult
β-Interferon
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Patients with multiple sclerosis (MS) require lifelong therapy. However, success of disease‐modifying therapies is dependent on patients' persistence and adherence to treatment schedules. In the setting of a large multicenter observational study, we aimed at assessing multiple parameters for their predictive power with respect to discontinuation of therapy. Materials and methods We analyzed 13 parameters to predict discontinuation of interferon beta‐1b treatment during a 2‐year follow‐up period based on data from 395 patients with MS who were treatment‐naïve at study onset. Besides clinical characteristics, patient‐related psychosocial outcomes were assessed as well. Results Among patients without clinically relevant fatigue, males showed a higher persistence rate than females (80.3% vs 64.7%). Clinically relevant fatigue scores decreased the persistence rate in men and especially in women (71.4% and 51.2%). Besides gender and fatigue, univariable and multivariable analyses revealed further factors associated with interferon beta‐1b therapy discontinuation, namely lower quality of life, depressiveness, and higher relapse rate before therapy initiation, while higher education, living without a partner, and higher age improved persistence. Conclusions Patients with higher grades of fatigue and depressiveness are at higher risk to prematurely discontinue MS treatment; especially, women suffering from fatigue have an increased discontinuation rate.
ISSN:0001-6314
1600-0404
DOI:10.1111/ane.12705